Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Semaglutide and Smoking in HIV
A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.
Tirzepatide Injection Route Error
A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.
Tirzepatide and TLR2 Inflammation in Mice
A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.
Adolescent GLP 1s: The Muscle Gap
A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.
Atypical anorexia after weight loss
A case report links severe restriction after sleeve gastrectomy, semaglutide, and tirzepatide with atypical anorexia nervosa.
Mounjaro hair loss: what trials show
Tirzepatide weight loss trials recorded hair loss in 4% to 5% of participants, compared with 1% on placebo.
Tirzepatide and Smoking Aversion
A 2026 case report linked tirzepatide initiation with abrupt sensory aversion to cigarettes and two years of reported smoking abstinence.
Diabetes Drugs and Cardiovascular Outcomes
A 93-trial network meta-analysis linked several diabetes drug classes with fewer cardiovascular events, while indirect comparisons limit treatment rankings.
GLP-1s and Neurodegeneration Reviewed
A 2026 narrative review finds biological promise for GLP-1-related drugs in neurodegeneration, but no established disease-modifying benefit.
GLP-1 Use in Serious Mental Illness
A 218,043-person retrospective cohort linked GLP-1 use with lower cardiovascular event and death risks in serious mental illness.
MASLD and MASH Drug Review
A 2026 narrative review separates approved MASH therapies from emerging candidates, including tirzepatide, while warning against cross-trial rankings.
Retatrutide Adverse Effects Online
A 2026 retatrutide social media study mapped self-reported symptoms but could not verify products, incidence, or causation.